Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | YTHDC1 | Q96MU7 | 7/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444616 | 1.00 | CDK1 (0.51) | CDK1CCNB1CCNE1CDK2P2RX7 | |
| SCHEMBL5158596 | 0.86 | P2RX7 (0.49) | CDK1CCNB1CCNE1CDK2P2RX7 | |
| SCHEMBL30332411 | 0.86 | P2RX7 (0.49) | CDK1CCNB1CCNE1CDK2P2RX7 | |
| SCHEMBL23547549 | 0.84 | CDK1 (0.50) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL25306748 | 0.84 | CDK1 (0.50) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL3440998 | 0.83 | CDK1 (0.71) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL15719927 | 0.83 | CDK1 (0.49) | CDK1CCNB1CCNE1CDK2P2RX7 | |
| SCHEMBL27854926 | 0.83 | CDK1 (0.71) | CDK1CCNB1CCNE1CDK2HSP90AA1 | |
| SCHEMBL5161283 | 0.82 | HDAC1 (0.49) | CDK1CCNE1CDK2P2RX7ADORA2A | |
| SCHEMBL183219 | 0.81 | HDAC1 (0.50) | CCNE1CDK2P2RX7YTHDC1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4634186-A1 | 2,6,9-TRISUBSTITUTED PURINES | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | TAIZHOU EOC PHARMA CO., LTD (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4444312-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240247001-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-07-25 | — | — | US | disclosed |
| CN-114149432-B | Dual CLK/CDK1 inhibitors for cancer treatment | 斯坦福国际研究院 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024127350-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023016477-A9 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2024-04-25 | — | — | WO | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030104974-A1 | Dual inhibitorsof PDE 7 and PDE 4 | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-05 | — | — | US | disclosed |
| US-20030100571-A1 | Purine inhibitors of phosphodiesterase (PDE) | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002102314-A2 | PURINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002088079-A2 | DUAL INHIBITORS OF PDE 7 AND PDE 4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088080-A2 | DUAL INHIBITORS OF PDE 7 AND PDE 4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-0874846-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997016452-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100571-A1 | Purine inhibitors of phosphodiesterase (PDE) | PDE7A, PDE7B, PDE3A | CDK1 1645/4885CCNB1 2865/4885CCNE1 3143/4885 |
| US-20030104974-A1 | Dual inhibitorsof PDE 7 and PDE 4 | PDE4A, PDE4B, PDE7B | CDK1 2181/4885CCNB1 4544/4885CCNE1 4588/4885 |
| US-20240247001-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | CDK1 2/4885CCNB1 24/4885CCNE1 23/4885 |
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | CDK2, CCNK, CDK1 | CDK1 3/4885CCNB1 44/4885CCNE1 36/4885 |
| US-12441744-B2 | 2,6,9-trisubstituted purines | CDK2, CDK1, CCNT2 | CDK1 2/4885CCNB1 24/4885CCNE1 23/4885 |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | CDK1 2/4885CCNB1 24/4885CCNE1 23/4885 |
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | CDK1 1472/4885CCNB1 2940/4885CCNE1 3733/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | CDK1 1075/4885CCNB1 3873/4885CCNE1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.